MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • MDS Virtual Congress 2021

    Blindness analyses in STEADY-PD3: a phase III placebo-controlled double-blind randomized trial of Isradipine as a disease modifying agent in early Parkinson Disease

    T. Mestre, S. Eberly, C. Grimes, D. Oakes, T. Simuni (Ottawa, Canada)

    Objective: To describe blindness for treatment allocation in STEADY-PD3 and understand the reasons for perceived treatment allocation. Background: The use of a placebo arm aims…
  • MDS Virtual Congress 2021

    Informing the design of disease modifying trials for Parkinson’s disease – A Delphi study

    M. Zeissler, R. Windle, K. Raphael, G. Rafaloff, K. Mcfarthing, H. Matthews, C. Carroll (Plymouth, United Kingdom)

    Objective: To assemble an international, multi-stakeholder Delphi panel to seek consensus on trial methodology for an adaptive trial platform investigating disease modifying therapies (DMTs) in…
  • MDS Virtual Congress 2021

    ABBV-0805, a novel α-synuclein oligomer selective antibody, prolonged lifespan and prevented accumulation of α-synuclein pathology in mouse models of Parkinson’s disease

    J. Fälting, F. Eriksson, J. Sigvardson, M. Johannesson, A. Kasrayan, M. Jones-Kostalla, P. Appelkvist, L. Söderberg, M. Blom, A. Rachalski, K. Nordenankar, O. Zachrisson, E. Amandius, G. Osswald, M. Moge, M. Ingelsson, J. Bergström, L. Lannfelt, C. Möller, M. Giorgetti, E. Nordström (Stockholm, Sweden)

    Objective: We report on the pharmacological characteristics of ABBV-0805 (BAN0805), a monoclonal antibody that exhibits a high selectivity for human α-synuclein oligomers and very low…
  • MDS Virtual Congress 2021

    Efficacy and safety of Levodopa-Carbidopa Intestinal Gel in the treatment of Parkinson’s Disease

    E. Londero, A P. Dos Santos, R. Braga, R. de Barros, L. Dos Reis, G. Freire (Salvador, Brazil)

    Objective: Our study aims to analyze the efficacy and safety of Levodopa-carbidopa intestinal gel (LCIG) in Parkinson's disease (PD). Background: Oral Levodopa is considered to…
  • MDS Virtual Congress 2021

    Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of safinamide: findings from the real-world OPTIPARK study

    N. Pavese, A. Lees, H. Reichmann, D. Martins, D. Magalhães, J. Rocha, P. Soares-da-Silva (Newcastle Upon Tyne, United Kingdom)

    Objective: This post-hoc analysis evaluated the effectiveness of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations (MF) according to baseline use of safinamide…
  • MDS Virtual Congress 2021

    Predictive factors of LCIG infusion therapy adherence – a single-center study of 103 consecutive LCIG patients

    V. Viljaharju, T. Mertsalmi, KAM. Pauls, M. Koivu, J. Eerola-Rautio, M. Udd, E. Pekkonen (Helsinki, Finland)

    Objective: The objectives of this study were to find predictive factors for early dropout from levodopa-carbidopa intestinal gel (LCIG) infusion in advanced Parkinson’s disease (PD)…
  • MDS Virtual Congress 2021

    Novel approach to MDS-UPDRS monitoring in clinical trials: Longitudinal Item Response Theory Models

    S. Luo, H. Zou, C. Goetz, D. Choi, D. Oakes, T. Simuni, G. Stebbins (Durham, USA)

    Objective: Using the unique advantages of Item Response Theory (IRT), we developed unidimensional and multidimensional models to investigate non-tremor and tremor MDS-UPDRS Part 3 changes…
  • MDS Virtual Congress 2021

    Investigation of the consultation status and clinical symptoms of patients with Parkinson’s disease after the spread of COVID-19

    M. Iijima, R. Morimoto, K. Kitagawa (Tokyo, Japan)

    Objective: This study investigated the consultation status and clinical symptoms of patients with Parkinson’s disease (PD) after the coronavirus disease 2019 (COVID-19) pandemic. Background: Due…
  • MDS Virtual Congress 2021

    Shannon entropy: a novel tool for assessing pentagon drawing in Parkinson’s disease

    L. Brabenec, P. Klobusiakova, J. Mekyska, I. Rektorova (Brno, Czech Republic)

    Objective: We used a digitizing tablet during PCT as a potential tool for assessing early cognitive deficits in PD yet without major cognitive impairment.  We…
  • MDS Virtual Congress 2021

    The retrograde procedural memory in people with Parkinson’s disease with or without freezing of gait – a cross-sectional study.

    L. Pauly, A. Rauschenberger, C. Pauly, M. Hansen, L. Pavelka, A. Hanff, V. Schröder, A. Leist, R. Krüger (Esch-Sur-Alzette, Luxembourg)

    Objective: To investigate the retrograde procedural memory in people with typical Parkinson’s disease (PwP) with or without freezing of gait (FOG). We hypothesized that the…
  • « Previous Page
  • 1
  • …
  • 410
  • 411
  • 412
  • 413
  • 414
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley